NRG Oncology Scientific Session

Research Review Hosted by the Publications Committee

Friday, July 13, 2018
8:00-10:00 AM ET

NRG Oncology July 2018 Semiannual Meeting
Philadelphia Marriott Downtown

PRESENTATIONS

Efficacy of chemotherapy for ER-negative and ER-positive isolated locoregional recurrence of breast cancer: Final analysis of the CALOR Trial.

Presenter: Irene L. Wapnir, MD
Discussant: Ruth O'Regan, MD

NRG Oncology RTOG 0126: A randomized phase III trial comparing standard and dose escalated radiation therapy for patients with intermediate risk prostate cancer.

Presenter: Jeff Michalski, MD
Discussant: Leonard Gomella, MD

Final Overall Survival (OS) Analysis of an International Randomized Trial Evaluating Bevacizumab (BEV) in the Primary Treatment of Advanced Ovarian Cancer: A NRG Oncology/Gynecologic Oncology Group (GOG) study.

Presenter: Krishnansu S. Tewari, MD (Robert Burger 1st Author)
Discussant: Kathleen Moore, MD

Long-term Results of NRG Oncology RTOG 0236: A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in Medically Inoperable Stage I Non-Small Cell Lung Cancer.

Presenter: Robert Timmerman, MD
Discussant: Clifford Robinson, MD

Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704.

Presenter: Chandan Guha, MD, Yaacov Lawrence 1st Author
Discussant: Terrance Williams, MD

Patient-reported toxicity during pelvic IMRT: NRG Oncology-RTOG 1203.

Presenter: Ann H. Klopp, MD
Discussant: Patricia Ganz, MD

Register for the semiannual meeting on the NRG Oncology website